Now showing items 1-1 of 1

    • Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity 

      Dufva, O; Koski, J; Maliniemi, P; Ianevski, A; Klievink, J; Leitner, J; Pölönen, P; Hohtari, H; Saeed, K; Hannunen, T; Ellonen, P; Steinberger, P; Kankainen, M; Aittokallio, T; Keränen, MAI; Korhonen, M; Mustjoki, S (American Society of Hematology, 2020)
      Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refractory B-cell malignancies, but resistance and relapses still occur. Better understanding of mechanisms influencing CAR T-cell ...
      Tieteelliset aikakauslehtiartikkelit